Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
Experienced Life Sciences Executive Brings Extensive Public and Private Company Experience to Support Company’s Growth Strategy
Ewing, NJ – May 6, 2026 – Orcosa Inc., a life-sciences company modernizing the way medicines are taken through the Rapid Infusion Technology (RITe™) Platform, today announced the appointment of Andy Drechsler as Chief Financial Officer.
As CFO, Mr. Drechsler will oversee all financial functions, including strategic planning, capital markets activities and fundraising, investor relations, and financial operations, as well as partner with the leadership team as it executes its corporate strategy.
“We are thrilled that Andy has decided to join Orcosa at such an important time for our company,” said Bryan Ridall, Co-Founder and Chief Executive Officer of Orcosa. “Andy’s proven track record of building successful biopharmaceutical companies, executing complex financing transactions, and guiding organizations through critical regulatory and financial milestones makes him the ideal person to help us advance a portfolio of differentiate products designed to meaningfully improve care for patients.”
“Orcosa’s business model and technology platform are truly compelling,” said Mr. Drechsler. “The company has built a strong foundation with validated clinical data, patent protection, and a clear regulatory pathway for ORC-144. I’m excited to join the entire Orcosa team and contribute to advancing innovative therapies that address unmet needs in patient care.”
About Andrew Drechsler
Mr. Drechsler brings 30 years of financial and operational leadership experience in the life sciences industry. He also currently serves as acting CFO for Altesa BioSciences. From 2017 to 2021, he was CFO of Provention Bio, where he helped build the company from 5 to 85 employees, led the acquisitions of two assets, completed an IPO in July 2018, and raised over $300 million in equity capital. Provention Bio was acquired by Sanofi in 2023. Prior to Provention, Mr. Drechsler served as CFO of Insmed Incorporated (Nasdaq: INSM) from 2012 to 2017. He also held the CFO position at Valera Pharmaceuticals, where he successfully completed its IPO in February 2006 and ultimately sold the Company to Indevus Pharmaceuticals.
Mr. Drechsler currently serves on the Board of Directors of Manasquan Bank, where he chairs the Audit Committee. He previously served on the Board of Baudax Bio. He holds a BS in Accounting, Magna Cum Laude, from Villanova University.
About Orcosa
Orcosa Inc. is a life sciences company modernizing the way medicines are taken and improving patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform. Orcosa is the inventor, developer and exclusive owner of the RITe™ Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa’s lead program is focused on developing a non-addictive pain management product, with additional products in development across areas where improved deliver, faster onset, and ease of administration may provide meaningful benefits to patients. For more information on Orcosa, please visit https://www.orcosa.com.
Media Contact
media@orcosa.com
Investor Contact
IR@orcosa.com